Lead Product(s) : Oxyntomodulin Analog
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Entera and OPKO Share PK/PD Results for Oral GLP-1 Peptide Candidate for Obesity
Details : OXM is a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Product Name : OXM
Product Type : Peptide
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Oxyntomodulin Analog
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Teduglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : OPKO Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs, including Teduglutide, the only approved GLP-2 analog, for the development of oral tablet formulations using Entera’s proprietary ora...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
December 09, 2023
Lead Product(s) : Teduglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : OPKO Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cannabidiol,5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Clearmind Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Weight Loss Treatment: SciSparc's Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Details : The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity...
Product Name : SCI-210
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Cannabidiol,5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Clearmind Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Univo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion
Details : New pre-clinical data demonstrating that cannabis derived CBD enriched fractions, supplied by Univo Pharmaceuticals, inhibit the expansion of human fat cells (pre-adipocytes) by 60%.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 03, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Univo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable